Literature DB >> 8576907

The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones.

T M Willson1, J E Cobb, D J Cowan, R W Wiethe, I D Correa, S R Prakash, K D Beck, L B Moore, S A Kliewer, J M Lehmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8576907     DOI： 10.1021/jm950395a

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  111 in total

1.  IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1.

Authors:  A C Bendixen; N K Shevde; K M Dienger; T M Willson; C D Funk; J W Pike
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-20       Impact factor: 11.205

Review 2.  Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developments.

Authors:  A J Scheen
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

3.  Discrete roles for peroxisome proliferator-activated receptor gamma and retinoid X receptor in recruiting nuclear receptor coactivators.

Authors:  W Yang; C Rachez; L P Freedman
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

Review 4.  Targeting orphan nuclear receptors for treatment of metabolic diseases and autoimmunity.

Authors:  Thomas P Burris; Scott A Busby; Patrick R Griffin
Journal:  Chem Biol       Date:  2012-01-27

5.  High-throughput Giardia lamblia viability assay using bioluminescent ATP content measurements.

Authors:  Catherine Z Chen; Liudmila Kulakova; Noel Southall; Juan J Marugan; Andrey Galkin; Christopher P Austin; Osnat Herzberg; Wei Zheng
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

6.  Frequency and significance of Pro12Ala and Pro115Gln polymorphism in gene for peroxisome proliferation-activated receptor-gamma regarding metabolic parameters in a Caucasian cohort.

Authors:  A Schäffler; N Barth; G Schmitz; B Zietz; K D Palitzsch; J Schölmerich
Journal:  Endocrine       Date:  2001-04       Impact factor: 3.633

7.  Open channel block of Kv1.3 by rosiglitazone and troglitazone: Kv1.3 as the pharmacological target for rosiglitazone.

Authors:  Hye Sook Ahn; Sung Eun Kim; Hyun-Jong Jang; Myung-Jun Kim; Duck-Joo Rhie; Shin-Hee Yoon; Yang-Hyeok Jo; Myung-Suk Kim; Ki-Wug Sung; Seong Yun Kim; Sang June Hahn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-11-21       Impact factor: 3.000

8.  Effect of ciprofloxacin and ibuprofen on the in vitro metabolism of rosiglitazone and oral pharmacokinetics of rosiglitazone in healthy human volunteers.

Authors:  J N Suresh Kumar; Prameela Devi; Lakshmi Narasu; Ramesh Mullangi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Oct-Dec       Impact factor: 2.441

9.  Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models.

Authors:  Ranjan Chakrabarti; Reeba K Vikramadithyan; Parimal Misra; Jagadheshan Hiriyan; Suryaprakash Raichur; Ravi K Damarla; Cynthia Gershome; Juluri Suresh; Ramanujam Rajagopalan
Journal:  Br J Pharmacol       Date:  2003-09-01       Impact factor: 8.739

10.  15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) and ciglitazone modulate Staphylococcus aureus-dependent astrocyte activation primarily through a PPAR-gamma-independent pathway.

Authors:  Nirmal K Phulwani; Douglas L Feinstein; Vitaliy Gavrilyuk; Candan Akar; Tammy Kielian
Journal:  J Neurochem       Date:  2006-12       Impact factor: 5.372
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.